Ananthakrishnan Ashwin N, Whelan Kevin, Allegretti Jessica R, Sokol Harry
Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Department of Nutritional Sciences, King's College London, London, United Kingdom.
Clin Gastroenterol Hepatol. 2025 Feb;23(3):406-418. doi: 10.1016/j.cgh.2024.05.049. Epub 2024 Jul 9.
Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize the current evidence on the role of the gut microbiome and diet in IBD pathogenesis, and the potential of microbiome-directed therapies and dietary interventions to improve IBD outcomes. We discuss available data and the advantages and drawbacks of the different approaches to manipulate the gut microbiome, such as fecal microbiota transplantation, next-generation and conventional probiotics, and postbiotics. We also review the use of diet as a therapeutic tool in IBD, including the effects in induction and maintenance, special diets, and exclusive enteral nutrition. Finally, we highlight the challenges and opportunities for the translation of diet and microbiome interventions into clinical practice, such as the need for personalization, manufacturing and regulatory hurdles, and the specificity to take into account for clinical trial design.
炎症性肠病(IBD)包括胃肠道的慢性复发性疾病,其特征是对肠道微生物群的免疫反应失调。肠道微生物群和饮食是影响IBD发病和进展的关键环境因素,可用于治疗。在本综述中,我们总结了关于肠道微生物群和饮食在IBD发病机制中的作用,以及微生物群导向疗法和饮食干预改善IBD结局的潜力的现有证据。我们讨论了现有数据以及不同方法操纵肠道微生物群的优缺点,如粪便微生物群移植、新一代和传统益生菌以及后生元。我们还综述了饮食作为IBD治疗工具的应用,包括诱导和维持效果、特殊饮食和全肠内营养。最后,我们强调了将饮食和微生物群干预转化为临床实践的挑战和机遇,如个性化需求、制造和监管障碍以及临床试验设计中需考虑的特异性。